Published Study Demonstrates Natera's Ability to Identify Heterogeneous Cancer Mutations in Patients with Early-Stage Lung Cancer

Go back to Published Study Demonstrates Natera's Ability to Identify Heterogeneous Cancer Mutations in Patients with Early-Stage Lung Cancer
(NASDAQ: NTRA) Delayed: 403.95 +2.58 (0.64%)
Previous Close $401.37    52 Week High $13.80 
Open $399.95    52 Week Low $6.52 
Day High $408.28    P/E N/A 
Day Low $395.33    EPS $0.00 
Volume 1,101,923